Elena Di Gennaro

List of Publications by Year
in descending order

44	1,852	236612	253896
papers	citations	25 h-index	43 g-index

45	45	45	3197
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors. Cancers, 2022, 14, 695.	1.7	3
2	HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. Journal of Experimental and Clinical Cancer Research, 2022, 41, 83.	3.5	19
3	HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. Molecular Oncology, 2021, 15, 1005-1023.	2.1	8
4	Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer. JAMA Network Open, 2021, 4, e2118475.	2.8	16
5	Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. Journal of Experimental and Clinical Cancer Research, 2020, 39, 213.	3.5	26
6	Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients withRAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092958.	1.4	10
7	Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. Frontiers in Cell and Developmental Biology, 2020, 8, 732.	1.8	22
8	Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors.. Journal of Clinical Medicine, 2019, 8, 912.	1.0	36
9	Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. Molecular Cancer Therapeutics, 2019, 18, 1405-1417.	1.9	18
10	A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. Scientific Reports, 2018, 8, 5823.	1.6	38
11	Synthesis and Evaluation of the Antitumor Properties of a Small Collection of Pt^{II} Complexes with 7â€Deazaadenosine as Scaffold. European Journal of Organic Chemistry, 2017, 2017, 4935-4947.	1.2	10
12	Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. Amino Acids, 2017, 49, 517-528.	1.2	9
13	Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. Journal of Experimental and Clinical Cancer Research, 2017, 36, 177.	3.5	33
14	Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. BMC Cancer, 2016, 16, 918.	1.1	60
15	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization) Tj ETQq1 1 0.784314 rgBT /O	1.1	18
16	Endothelial progenitor cells, defined by the simultaneous surface expression of <scp>VEGFR</scp>2 and <scp>CD</scp>133, are not detectable in healthy peripheral and cord blood. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 259-270.	1.1	51
17	Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget, 2016, 7, 7715-7731.	0.8	67
18	Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget, 2016, 7, 19559-19574.	0.8	20

#	Article	IF	Citations
19	Synthesis and Evaluation of the Antiproliferative Properties of a Tethered Tubercidinâ€“Platinum(II) Complex. European Journal of Organic Chemistry, 2015, 2015, 7550-7556.	1.2	6
20	Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Free Radical Biology and Medicine, 2015, 89, 287-299.	1.3	73
21	Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle, 2014, 13, 652-665.	1.3	36
22	Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.3	37
23	New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent. Cancer Treatment and Research, 2014, 159, 355-376.	0.2	119
24	Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opinion on Drug Safety, 2014, 13, 113-129.	1.0	30
25	Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids, 2013, 44, 63-72.	1.2	52
26	Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death and Disease, 2013, 4, e641-e641.	2.7	57
27	Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death and Disease, 2013, 4, e878-e878.	2.7	50
28	Caveolinâ€1 overexpression is associated with simultaneous abnormal expression of the Eâ€cadherin/Î±â€“Î² catenins complex and multiple erbb receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. Journal of Cellular Physiology, 2012, 227, 3344-3353.	2.0	40
29	Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hepâ€2 cancer cells. Proteomics, 2011, 11, 3725-3742.	1.3	21
30	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. Journal of Cellular Physiology, 2011, 226, 2378-2390.	2.0	139
31	Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agents. European Journal of Medicinal Chemistry, 2011, 46, 2206-2216.	2.6	11
32	Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. British Journal of Cancer, 2010, 103, 1680-1691.	2.9	42
33	Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 1-13.	0.8	18
34	Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed. Cancer Biology and Therapy, 2009, 8, 782-791.	1.5	65
35	Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Molecular Cancer Therapeutics, 2009, 8, 3075-3087.	1.9	104
36	Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. Anti-Cancer Drugs, 2007, 18, 781-791.	0.7	15

#	Article	IF	Citations
37	Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 2007, 2, 119-134.	0.8	51
38	Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-Î± in Head and Neck Cancer Cells In vitro and In vivo. Clinical Cancer Research, 2006, 12, 617-625.	3.2	88
39	Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase. Current Drug Targets, 2005, 6, 337-351.	1.0	33
40	Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. Journal of Pathology, 2004, 204, 317-325.	2.1	93
41	Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (?Iressa?), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. Journal of Cellular Physiology, 2003, 195, 139-150.	2.0	127
42	EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-Î±-mediated apoptosis in epidermoid cancer cells. Cell Death and Differentiation, 2003, 10, 218-229.	5.0	67
43	Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: A phase Iâ€“II trial of the Southern Italy Cooperative Oncology Group (SICOG). Annals of Oncology, 2000, 11, 575-580.	0.6	8
44	Up-regulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-Cl-cAMP. FEBS Letters, 1999, 447, 203-208.	1.3	4